Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Oragenics Inc.

Conduct pre-clinical animal studies for the Terra CoV-2 vaccine IND application

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
7 Jan 2021
Due
31 Mar 2021
Delivered
Q1 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“The initial agreement calls for TQL1055 to be used in pre-clinical animal studies supporting the U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) application expected to be conducted during the first quarter of”
  • SourceOragenics Inc. Form 8-K press release, 2021-01-07
  • FilingSEC filing index
  • Deadline as statedduring the first quarter of 2021
  • Deadline used31 Mar 2021, the last day of the stated period
  • TypeProject
  • Permanent referenceKI-C-2021-OGEN-021312
    Cite as https://keptindex.org/c/KI-C-2021-OGEN-021312/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company confirmed it conducted pre-clinical animal studies, including hamster virus challenge and mouse immunogenicity studies, which were completed to support the vaccine development program.

  • A
    Oragenics Inc. 10-K filed 2022-03-24 Regulatory filing · published 24 Mar 2022 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint d9ba3537f411
    “We have conducted the pre-clinical studies including the Syrian Hamster virus challenge study, the mouse immunogenicity study with positive results for both the intramuscular formulation (Terra CoV-2) and the intranasal formulation (NT-CoV2-1).” ✓ confirmed on the page

Market reaction: the shares moved -13.5% against the S&P 500 over the three sessions around the disclosure (23 Mar 2022 to 28 Mar 2022). What this measures

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Project other
Indicative materiality
Low rules
Action
Conduct
Deliverable
pre-clinical animal studies
Where
U.S.
Language
Expected (“expects”, “plans”)
In the company’s control
High
Specificity
High
Conditional
Yes: subject to material transfer agreement
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
  4. Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Oragenics Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-OGEN-021312 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.